Profile cover photo
Profile photo
Advanced Technology Platforms for Neuromodulation Therapy Developers
Advanced Technology Platforms for Neuromodulation Therapy Developers

Communities and Collections
View all

Post has attachment
Senior-Level Neuromodulation Executive Joins AdvaStim

George Cintra, former CTO of Integer, joins AdvaStim to expand alliance partnerships and commercialization opportunities

BOSTON--(BUSINESS WIRE)--AdvaStim, Inc.,, a leading developer of ASIC-based technology platforms for neuromodulation therapies, announced today that George Cintra has joined the company as Strategic Advisor for Technology and Business Development. Mr. Cintra has more than 25 years of experience leading product development, engineering and business development functions in the medical device and consumer products industries.

George Cintra, former CTO of Integer, joins AdvaStim to expand partnerships and commercialization opportunities

“Having someone of George’s extensive industry background join our team demonstrates the exciting commercial potential that our technology promises to the neuromodulation device field,” said Laurence Derose, CEO and Co-founder of AdvaStim. “Our ASIC-based platform can potentially open new avenues and approaches for targeted neurostimulation therapies, and George’s extensive industry contacts and long experience in the field can help us best leverage these opportunities.”

“AdvaStim’s ASIC-based technology represents a breakthrough for neuromodulation therapeutic systems to expand into a variety of clinical indications,” said George Cintra. “I’m excited to join AdvaStim and help further this technology for the next generation of neuromodulation therapy options.”

Mr. Cintra was the Executive Vice President and Chief Technology Officer at Integer Holdings, Inc. (formerly Greatbatch Medical), a global leader in the design and development of implantable medical devices, from 2013 through January 2016, and served in an advisory capacity through January 2017. In addition to leading research, development, engineering and regulatory & clinical affairs, he also led the QiG Group and CCC Medical Devices subsidiaries for the company. Prior to Integer, he had a 16-year career holding technology and product development positions at P&G, Gillette, and Duracell. He has been awarded 39 U.S. and foreign patents across a broad range of power systems and electromechanical products. Mr. Cintra earned his B.S. in chemical engineering and completed graduate studies at Carnegie Mellon and the University of Virginia.

About AdvaStim, Inc.
AdvaStim is a technology developer addressing the multi-billion dollar neurostimulation market with a disruptive hardware/software technology platform to help emerging device companies effectively implement the next generation of implantable device therapeutics. For more information, visit

AdvaStim, Inc.
Laurence Derose, 413-575-5849
KCSA Strategic Communications
Paul Sagan, 617-852-0495
Commenting is disabled for this post.

Post has attachment

Post has attachment
Smithsonian – Inside the Science of an Amazing New Surgery Called Deep Brain Stimulation

The most futuristic medical treatment ever imagined is now a reality

Like most people in need of major surgery, Rodney Haning, a retired telecommunications project manager and avid golfer, has a few questions for his doctors. He wonders, for example, exactly how the planned treatment is going to alleviate his condition, a severe tremor in his left hand that has, among other things, completely messed up his golf game, forcing him to switch from his favorite regular-length putter to a longer model that he steadies against his belly.

billboard-may14_e02_deepbrain.jpg__800x600_q85_crop“Can anyone tell me why this procedure does what it does?” Haning asks one winter afternoon at UF Health Shands Hospital, at the University of Florida in Gainesville.

“Well,” says Kelly Foote, his neurosurgeon, “we know a lot, but not everything.”

The vague answer doesn’t seem to bother Haning, 67, an affable man who has opted for the elective brain surgery. And it’s hard to fault Foote for not going into greater detail about the underlying science, since he is, at that very moment, boring a hole in Haning’s skull.

“Can you hear the drill?” Foote asks his patient as he presses the stainless steel instrument against bone. When Haning, whose head is immobilized by an elaborate arrangement of medical hardware, asks why it doesn’t hurt to have a dime-size hole drilled in his skull, Foote calmly explains that the skull has no sensory nerve receptors. (The doctors numb his scalp before making the incision.)

The two continue to chat as Foote opens the dura—“It’s the water balloon that your brain lives in,” he says. “It’s sort of like a tough leather, for protection”—and exposes Haning’s brain.

Deep brain stimulation, or DBS, combines neurology, neurosurgery and electrical engineering, and casual conversations in the operating room between doctors and their wide-awake patients are just one of the surprises. The entire scene is an eerie blend of the fantastic and the everyday, like something from the work of Philip K. Dick, who gave us the stories that became Blade Runner and Total Recall. During surgery, DBS patients are made literally bionic. Tiny electrodes are implanted in their brains (powered by battery packs sewn into their chests) to deliver a weak but constant electric current that reduces or eliminates their symptoms. DBS can improve a shaky putting stroke; it can also help the disabled walk and the psychologically tormented find peace.

Read more:

Post has attachment
Tapping Electrical Signals: Turning Thought Into Action

Like most things, mind reading comes down to the quality of your equipment.

To turn thought into action, sensors must read the brain's noisy electrical signals, and then feed them to a computer, which decodes the signals and turns them into commands. While researchers have made many helpful mind-controlled machines, most sensors in use today are imprecise.

Post has attachment
More Contacts, More Relief Says New Spinal Cord Stimulation Research

A new device for spinal cord stimulation (SCS) offer spatients increased pain relief by adding more electrical contacts in the epidural space. In addition to reduced pain, patients also showed improved walking tolerance and decreased disability.

“The primary objective of SCS is pain relief,” said Salim Hayek, MD, PhD, chief of the Division of Pain Medicine at University Hospitals of Cleveland, in a statement. “These initial results indicate that the Precision Spectra System is effectively reducing pain in these real-world patients at three months post-implant.”

Read more here:

Post has attachment
AdvaStim’s CTO Barry Yomtov Presents at Neurotech Investing & Partnering Conference

On April 23, AdvaStim’s Chief Technical Officer and co-founder, Barry Yomtov will present at the 9th Annual Neurotech Investing & Partnering Conference in Boston at the Ritz Carleton Hotel. This is the premier partnering and investing conference for the neurotechnology industry including pharmaceuticals, medical devices and diagnostics and will focus on Advances in Drugs, Devices and Diagnostics for the Brain and Nervous System.  

Read more here:

Barry will present at the session titled, New Developments in Chronic and Neuropathic Pain. The session will focus on drugs and devices with novel mechanisms of action and emerging treatment options that are on the horizon to decrease side effects and improve efficacy in chronic and neuropathic pain.  Presenting along with AdvaStim will be executives from Autonomic Technologies, Soterix Medical, and Trigemina, moderated by Kiran Reddy, Associate Partner at Third Rock Ventures.

The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.

Post has attachment
AdvaStim Enters Neuromodulation Device Market

AdvaStim’s novel hardware and software platform gives developers capabilities to address current and emerging clinical indications.

BEVERLY, Mass., April 23, 2014:  AdvaStim, Inc.,, a leading developer of advanced technology platforms for neuromodulation therapies, announced today that the Company has entered the research and development market with a new hardware/software solution for neuromodulation therapy developers.

“AdvaStim was formed to address the multi-billion-dollar neurostimulation market with a hardware and software platform to help device companies and clinician researchers develop the next generation of implantable therapeutics,” said Laurence Derose, Founder of AdvaStim.

Post has attachment
FDA OK for spinal cord stimulation system

Minneapolis, Minn. - St. Jude Medical Inc. officials announce approval of its Protégé IPG from the U.S. Food and Drug Administration (FDA). Protégé is the first and only neurostimulation system that allows spinal cord stimulation (SCS) technology upgrades as they are approved to be made via software updates. Chronic pain sufferers implanted with this new device can access innovative therapies, stimulation modes, diagnostics, or other features once approved through future software upgrades – without the need to surgically replace their medical device.

Read more here:

Post has attachment
When Spine Implants Cause Paralysis, Who Is to Blame?

Spinal-Cord Simulators Are Intended to Relieve Pain

Rick Greenwood checked in for an overnight stay at a Dallas hospital two years ago to have a spinal-cord stimulator implanted in his back. The surgery was meant to relieve the back pain that had troubled him for more than 40 years, but when he left the hospital one month later, he was pushed out in a wheelchair, paralyzed from the waist down.

Read more here:

Post has attachment
Early intervention key to treating Parkinson’s disease

The earlier the disease is detected and the treatment process begins, the better quality of life patients often experience.

Fortunately, there have been many advancements in surgical treatment for Parkinson’s disease.

A procedure known as deep brain stimulation (DBS) has been extremely successful in the treatment and management of Parkinson’s disease, and for the right candidates, serves as a good compliment to the medications also being used to treat the disease.

Read more here:
Wait while more posts are being loaded